ICU Weekly
Issue #01May 11, 2026

High-yield critical care science, written every week

Sepsis, ventilation,and what is new and trustworthyin the literature.

This inaugural edition brings together the studies that matter most at the bedside: from ANDROMEDA-SHOCK-2 — which repositioned capillary refill time as a resuscitation target — to the 2026 Surviving Sepsis Campaign guidelines. No hype. Only evidence that changes practice.

🔬This edition coversSepsis Resuscitation · Protective Ventilation & Driving Pressure · SSC Guidelines 2026 · ICU Delirium · Peripheral Vasopressors · Vitamin C in Sepsis

Featured articles

01
Multicenter RCTIF ~130JAMACEBM 1b

Personalized Hemodynamic Resuscitation Targeting Capillary Refill Time in Early Septic Shock — The ANDROMEDA-SHOCK-2 Randomized Clinical Trial

JAMA · October 2025 · n = 1,501 patients · 86 ICUs · 19 countries

A randomized, controlled trial conducted across the Americas, Asia, and Europe between March 2022 and April 2025. Patients with early septic shock were allocated to resuscitation guided by capillary refill time (CRT ≤ 3 seconds as target) versus usual care based on current guidelines.

The primary outcome was a hierarchical composite of 28-day mortality, duration of vital support, and hospital length of stay — an analytical method that captures gradations of clinical benefit that traditional binary endpoints miss.

DOI 10.1001/jama.2025.20402View original article
02
Systematic ReviewMeta-analysisIF ~15Critical CareCEBM 1a

Driving Pressure-Limited Ventilation Strategies versus Conventional Lung Protective Ventilation Strategies for ARDS/ARF: A Systematic Review and Meta-analysis of RCTs

Critical Care — Springer Nature · 2025 · 4 RCTs included · n = 465 patients

A systematic review with meta-analysis of randomized clinical trials comparing ventilation strategies targeting driving pressure (DP ≤ 15 cmH₂O) versus conventional lung-protective ventilation (low tidal volume without DP as a primary target) in patients with ARDS or acute respiratory failure.

Search across major databases from inception through June 2025. Primary outcome: short-term mortality. Methodological quality assessed using Cochrane RoB 2 tool and GRADE framework.

DOI 10.1186/s13054-025-05722-yView original article
03
International GuidelineIF ~40ICM + CCMCEBM 2a

Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2026

Intensive Care Medicine + Critical Care Medicine · 2026 · 129 statements · 46 new · 24 endorsing societies · 130+ international experts

An update to the SSC 2021 guidelines, developed by international panels with representation from all continents, including patients and family members. GRADE methodology with support from the GUIDE group. Simultaneously published in Intensive Care Medicine and Critical Care Medicine.

The 46 new statements include antibiotic optimization, blood pressure targets in older adults, fluid removal after resuscitation, and post-discharge continuity of care — with explicit attention to physical and psychological rehabilitation.

DOI 10.1007/s00134-026-08361-1View original article

Also in this edition

04
Phase 2b RCTCEBM 1b

Ascorbate for Organ Dysfunction in Critically Ill Patients With Sepsis: The Phase 2b ASTER Trial

CHEST Critical Care · September 2025 · n = 79 (terminated early)

Randomized, placebo-controlled phase 2b trial (n = 79, terminated early). Ascorbic acid 50 mg/kg IV every 6 hours for 5 days vs. placebo in patients with suspected/confirmed infection and shock or acute respiratory failure. Trial was halted following publication of a separate study showing a mortality signal with ascorbate in septic shock. Primary outcome (organ failure-free days): negative. Reduced inflammatory biomarkers, but no clinical impact.

View original articledoi.org/10.1016/j.chstcc.2025.100168
05
Meta-ReviewCEBM 1a

Systematic Meta-Review of Interventions to Prevent and Manage Delirium in the ICU: Part 2 — Non-Pharmacological and Multicomponent Interventions

Critical Care — Springer · 2025

Comprehensive meta-review (OPTIC Consortium) searching 8 databases through August 2025. Evaluated non-pharmacological and multicomponent interventions for ICU delirium. Conclusion: the ABCDEF bundle and multicomponent strategies significantly reduce delirium incidence and duration. Single-component interventions (early mobilization, family presence, reorientation) show benefit in before-after studies, but not consistently in stand-alone RCTs — reinforcing that the bundle works as a system, not as isolated parts.

View original articledoi.org/10.1186/s13054-025-05726-8
06
Feasibility RCTCEBM 1b*

A Randomised, Controlled, Feasibility Trial Comparing Vasopressors via Peripheral Cannula versus Central Venous Access for Critically Ill Adults: The VIPCA Trial

Critical Care and Resuscitation · 2025 · n = 40

Feasibility RCT (n = 40; 20 per group) comparing vasopressor infusion via peripheral IV catheter (PIVC) versus central venous catheter (CVC). PIVC was safe: 20% minor complication rate (leakage/tissuing), no serious adverse events (necrosis, surgery). Protocol adherence was significantly lower in the early CVC group (55% vs 100%). Methodological note: classified CEBM 1b with asterisk as a feasibility trial — a definitive effectiveness trial is still needed before this practice can be universally adopted.

View original articledoi.org/10.1016/j.ccrj.2025.100106

Quick hits · clinical pearls

🧬Pearl · biomarkers

Biomarker enrichment in sepsis trials

A 2025 systematic review (Critical Care) showed that biomarker-based enrichment can identify sepsis subgroups with higher probability of response to targeted interventions. Procalcitonin, IL-6, and host RNA biosignatures emerge as leading candidates for precision trials. The implication: the next step in sepsis research is not "treat everyone the same."

🫁Pearl · ventilation

Open lung vs ARDSNet: the debate continues

A 2025 meta-analysis (Critical Care Research & Practice) compared open lung ventilation — low tidal volume plus staircase recruitment maneuvers plus high decremental PEEP — with ARDSNet. No mortality reduction, but less rescue ventilation and a trend toward improved oxygenation. A sufficiently powered definitive trial is still missing from the literature.

🧠Pearl · delirium

No drug prevents ICU delirium

The OPTIC pharmacological meta-review (Critical Care, 2025): no pharmacological intervention — including haloperidol, dexmedetomidine, melatonin, or atypical antipsychotics — reduced ICU mortality. Dexmedetomidine reduces delirium incidence but carries relevant hemodynamic adverse effects. The message is clear: the care environment and the ABCDEF bundle still outperform any drug.

🚶Pearl · mobilization

Early mobilization on vasopressors: safer than we thought

A prospective cohort study demonstrated that early active mobilization in critically ill adults receiving vasopressor or inotropic support is feasible and safe when guided by structured assessment protocols — no ICP elevation or clinically significant hemodynamic instability was observed. This challenges the mental barrier of "vasopressor = absolute rest."

Resources

Closing note

The people who are crazy enough to think they can change the world are the ones who do.

Steve Jobs — Stanford Commencement Address, 2005

Every shift is an opportunity to apply the best science has to offer — not because a protocol demands it, but because that is the standard you have chosen for yourself. Keep questioning, keep learning, keep being better than you were yesterday.

— Caroline

Next edition — Issue #02

Coming up in ICU Weekly

  • · Cardiac arrest resuscitation — what is new in CPR and post-ROSC care
  • · Transfusion thresholds in critical illness — current evidence
  • · Neurointensive care — sedoanalgesia and multimodal monitoring
  • · HAP and VAP — when the microbiome surprises you